Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation - Wikidata - awgldk - TriplyDB

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

http://www.wikidata.org/entity/Q33400803

about

Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.Relapsed Hodgkin lymphoma: management strategies Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.Brentuximab vedotin treatment for primary refractory hodgkin lymphoma.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.Advances in the treatment of hematologic malignancies using immunoconjugates Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.Advances in the treatment of Hodgkin lymphoma.Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.Challenges and approaches for the development of safer immunomodulatory biologics.CD30 as a therapeutic target for lymphoma.Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Role of CD30 targeting in malignant lymphoma.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.Hodgkin's Lymphoma in Older Patients: an Orphan Disease?Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

P2860

Q26772848-5692E9A2-9F83-4914-B521-43F3654FCFE3 Q26993238-AA62A706-C835-4AD1-8E67-CFEE8219BA3E Q27003258-62134CC6-E740-48A4-A395-4E4D463788C5 Q27022992-BFC58296-67C0-4A61-887F-0C0476AC1E51 Q28087540-6EEB6E50-B159-4986-BCA8-8C116739669B Q30240160-B563AB5E-2AD1-4A1D-AFE0-3B6780A59753 Q33411127-764B70F1-0A92-40AA-9099-D99B84231FC7 Q33420273-811634F5-8032-4185-9861-7BED8DAFC1CD Q33886267-D2CAEF99-74FD-4631-BDF1-B3BAE7C3AC2C Q34655256-22F71A18-A78D-45B4-B1EC-7BECCBE489E3 Q35223221-97E2B419-633D-45AF-9748-5E688C142E74 Q36232484-97DDAEB7-AC6F-4AAB-9FA4-5C311CACF491 Q36585636-80381DAF-A13B-40CC-9041-0D30489532C3 Q36979534-25ECB74E-90A9-479C-95F1-E94DE1163C6B Q37008427-6489F3F5-078E-4CBE-82D9-B952C80DAC0E Q37098302-EF83FD4C-B91F-4FDF-8F00-17722DF59135 Q37216260-7756300C-EE50-4123-8C25-A2C24657CAAC Q37254777-E60BEE8F-839E-423F-85D9-1A11DB2F0F66 Q37412853-DB691BF7-8AC4-4C75-8498-A7C087AF8087 Q37649035-38A7C0D0-D93C-42EF-8D67-51C352E22D72 Q37697843-E37E943B-B1F2-43CB-9380-B00FF2E2CB16 Q37715109-5121C84F-0E91-46CA-A514-BC2385587E4B Q38051197-881CB8C0-BFEA-4463-B42F-D9CB3F2F72F3 Q38073207-AFA04C55-AE9B-4EE0-AF8C-2FBD32EADEFF Q38093772-F8C9F9DD-0499-47C8-84EE-615983ADF2FB Q38138482-2058763A-D1BE-4C17-9102-4EE42244946C Q38164572-F337DF75-72DE-4C03-993C-1A617F4DC324 Q38176398-19C90350-962A-47F8-9A5C-A25FF8DA9BB2 Q38191191-CE8C2F52-A7A9-4D83-8433-70DBA6053A6F Q38205923-E6338D12-308B-4DFA-B7DC-C762C6E4400E Q38227567-338F5159-5D98-44B4-BDFD-3D49DA8C9E26 Q38232075-4CC6F7F2-828D-44CD-BF5D-F6952F17A377 Q38340900-7FAC7780-70EF-4643-AF81-D20A65B90981 Q38361620-CB87D70F-062B-4634-81D9-09F522014020 Q38368587-1F266078-67EC-488E-A632-37885ABEC3E6 Q38466376-2E508DF8-A2F5-43BC-8DA9-2E0029D94132 Q38476250-F8F9DB0C-B0FC-4E9E-AEA6-BAD5F3AAF1B1 Q38557033-071B9293-0674-46DB-8F5F-86CF652BA41C Q38664909-4E8EC3B7-32B7-433F-862C-7680523ED040 Q38721642-0C8BB930-671C-4A37-B31A-9DA079A3AAF6

P2860

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

http://www.wikidata.org/entity/Q33400803

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Safety and efficacy of brentux ...... neic stem cell transplantation

@ast

Safety and efficacy of brentux ...... neic stem cell transplantation

@en

type

label

Safety and efficacy of brentux ...... neic stem cell transplantation

@ast

Safety and efficacy of brentux ...... neic stem cell transplantation

@en

prefLabel

Safety and efficacy of brentux ...... neic stem cell transplantation

@ast

Safety and efficacy of brentux ...... neic stem cell transplantation

@en

P1433

Q33400803-1573B1A2-5D63-4741-A4D3-45F0026076DF

P1476

Q33400803-FD665F47-73FB-4528-94AA-47070FAD4838

P2093

Q33400803-009AAAF6-A1DB-487E-B9BC-F395CF8ED804

Q33400803-0860AB35-6B40-4993-BE22-0FF0568AEB15

Q33400803-1A1E0D6F-B13B-424F-8C50-02B6AC66888E

Q33400803-1AA1FA91-8DAD-46BD-983F-D510F4E4FFD2

Q33400803-23F75AFD-6E25-4261-BD63-576883A5600D

Q33400803-2E58EF13-CFB9-4146-AB5B-C8DA2C9304AA

Q33400803-6B64F68F-7BB6-4D09-9B8E-78631CA1D11F

Q33400803-7EB6909E-402A-4C64-B68F-6374FC88953D

Q33400803-A3A0684C-BC81-48AC-BBB3-67356E0CBFC7

Q33400803-AF951A66-8C6B-4148-88BF-6B90417C7386

P2860

Q33400803-09CE5D80-EC04-45FD-BC4A-9FD4D0CBC688

Q33400803-10A18608-1A96-43E6-8037-AC4FD0C6CA9C

Q33400803-222EC60D-C5BD-4BBF-8A64-5CE3F31090E1

Q33400803-27B32328-B517-4928-BD36-6320725AD00B

Q33400803-28AE99F0-A852-4118-8FE8-6900D9A16342

Q33400803-2CAF9102-B907-460E-8538-5D6A6C632186

Q33400803-40A5E8A3-793E-444E-88D9-152DFC109A50

Q33400803-47D7DB0A-7422-4A5E-B950-2F300ABC2D00

Q33400803-4C844869-CD49-44F5-A02D-60866572BE72

Q33400803-4CB7132C-B3EC-4A10-914B-5F7C91343E7F

P304

Q33400803-8EF65136-146C-4025-AED5-C61FABF3AF35

P31

Q33400803-B2FB667D-2106-48A4-9C85-1DDFB106EDF6

P356

Q33400803-8CA0AC0A-A4DC-4BF7-9EB7-416699351BB1

P407

Q33400803-1E0C59DE-9CBB-4C57-B917-01777701AB87

P433

Q33400803-7C945FB5-82E3-4F5F-8025-B77636898776

P478

Q33400803-700F2221-7F22-450F-A57E-32AE0EB69049

P50

Q33400803-15E5A931-202D-4CCF-B9B8-949426C252DB

P577

Q33400803-686A3905-9711-4B8E-95CB-692B027B823A

P5875

Q33400803-69277DAB-CCED-4000-A321-880110015B98

P698

Q33400803-599EA476-17F4-4B92-8AE4-A00A701183A8

P932

Q33400803-30B4624C-B97E-41FF-8926-E0286C7CB87B

P356

BLOOD-2011-12-397893

P1433

P1476

Safety and efficacy of brentux ...... neic stem cell transplantation

@en

P2093

Achim Rothe

http://www.w3.org/2001/XMLSchema#string

Jasmine Zain

http://www.w3.org/2001/XMLSchema#string

Jeffrey V Matous

http://www.w3.org/2001/XMLSchema#string

Laurie E Grove

http://www.w3.org/2001/XMLSchema#string

Maureen Cooper

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

Radhakrishnan Ramchandren

http://www.w3.org/2001/XMLSchema#string

Ranjana H Advani

http://www.w3.org/2001/XMLSchema#string

Robert B Berryman

http://www.w3.org/2001/XMLSchema#string

Robert Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

P304

560-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-397893

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224284208

http://www.w3.org/2001/XMLSchema#string

P698

22510871

http://www.w3.org/2001/XMLSchema#string

P932

3731651

http://www.w3.org/2001/XMLSchema#string